Market closedNon-fractional
Regeneron/REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Ticker
REGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Tarrytown, United States
Employees
13,677
Website
www.regeneron.com
Regeneron Metrics
BasicAdvanced
$115B
Market cap
31.44
P/E ratio
$33.85
EPS
0.12
Beta
-
Dividend rate
Price and volume
Market cap
$115B
Beta
0.12
Financial strength
Current ratio
6.403
Quick ratio
5.719
Long term debt to equity
10.016
Total debt to equity
10.016
Interest coverage (TTM)
55.95%
Management effectiveness
Return on assets (TTM)
7.72%
Return on equity (TTM)
15.28%
Valuation
Price to earnings (TTM)
31.442
Price to revenue (TTM)
8.682
Price to book
4.25
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
28.942
Growth
Revenue change (TTM)
5.90%
Earnings per share change (TTM)
-7.95%
3-year revenue growth (CAGR)
12.51%
3-year earnings per share growth (CAGR)
-1.23%
What the Analysts think about Regeneron
Analyst Ratings
Majority rating from 29 analysts.
Regeneron Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.1B
-8.42%
Net income
$722M
-37.74%
Profit margin
22.95%
-32.02%
Regeneron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$10.24
$11.59
$11.86
$9.55
-
Expected
$9.84
$10.72
$10.73
$10.09
$10.59
Surprise
4.03%
8.13%
10.53%
-5.38%
-
Regeneron News
AllArticlesVideos
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
Accesswire·4 hours ago
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
Accesswire·1 day ago
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $115B as of July 27, 2024.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 31.44 as of July 27, 2024.
Does Regeneron stock pay dividends?
No, Regeneron (REGN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Regeneron dividend payment date?
Regeneron (REGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Regeneron stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.